Researchers have initiated a clinical trial using an investigational medicine to lower amyloid precursor protein, targeting Alzheimer's disease in adults with Down syndrome. The study aims to prevent the development of Alzheimer's disease by addressing its underlying genetic cause.
Researchers analyzed brain tissue from individuals with severe Tourette syndrome and identified three key changes: altered gene activity, regulatory element modifications, and interneuron loss. These findings provide unprecedented insights into the disorder's biology and may explain why individuals experience involuntary movements and ...
A new study from the University of Colorado Anschutz Medical Campus identified significant mitochondrial dysfunction in lymphoblast cell lines from children with Dravet syndrome, a severe form of epilepsy. The findings suggest that mitochondrial defects play a role in the metabolic dysfunction observed in Dravet syndrome.
A unique case study reveals an unexpected discrepancy between Alzheimer's pathology and cognitive function in a woman with Down syndrome. The study highlights the need to expand inclusion criteria for therapeutic drug trials and uncover genetic or lifestyle factors that contribute to cognitive preservation.
Mutations in MeCP2 gene lead to depletion of NEAT1, a long non-coding RNA controlling autophagy. Restoring NEAT1 reverses cellular alterations in Rett syndrome models.
A new study at George Washington University suggests daily cannabis use is associated with a syndrome that causes severe symptoms, including pain and repeated hospital trips. The condition, cannabinoid hyperemesis syndrome, affects individuals who start using cannabis in their teens and can lead to costly medical issues.
The American Heart Association has chosen five US regions to implement a new preventive health initiative aimed at improving care for people with cardiovascular-kidney-metabolic (CKM) syndrome. The initiative will increase awareness and screening for CKM syndrome and facilitate collaboration among healthcare professionals.
A new study published in Aging found that pioglitazone reduced the frequency of skin ulcers in Werner syndrome patients. The research suggests that pioglitazone's anti-inflammatory properties may help wounds heal faster and prevent ulcers from forming.
A massive study of human protein variants found that 61% of disease-causing mutations destabilize proteins, leading to cataracts, neurological disorders, and muscle-wasting diseases. The researchers created the Human Domainome 1 catalogue, which includes over half a million mutations across 522 human protein domains.
Researchers have identified the gene DYRK1A as a key driver of 'glue ear' in people with Down syndrome, a middle ear condition commonly known as otitis media with effusion. The discovery paves the way for future targeted therapies to address hearing loss in patients.
Researchers have identified molecular changes that occur long before symptoms appear, shedding light on the development of Rett syndrome. These findings hold promise for developing safe gene therapies and monitoring biomarkers to track MECP2 gene function.
A phase 1/2 clinical trial has demonstrated the safety and effectiveness of the AEF0217 molecule in improving cognitive function in people with Down syndrome. Measured outcomes showed significant improvements in behavioral skills, social interactions, and cognitive flexibility.
A study at Baylor College of Medicine and Texas Children's Hospital reveals that loss of MeCP2 function in adulthood causes immediate progressive dysregulation of hundreds of genes, some activated while others suppressed. Gene expression changes occur well before measurable neurological function deficiencies.
The $2.7 million grant will support a network of research sites across the US and Latin America, investigating clinical characteristics and potential differences in care for Latinos with Down syndrome. The study aims to identify risk and resiliency factors that could change the presentation of Down syndrome in diverse cultural contexts.
The Speech Accessibility Project is working with two new partners, The Matthew Foundation and the Massachusetts Down Syndrome Congress, to recruit adults with Down syndrome and other conditions. The project aims to provide voice command devices to improve inclusion and employment opportunities for individuals with disabilities.
A study found that people with excessive daytime sleepiness and a lack of enthusiasm are more likely to develop motoric cognitive risk syndrome, a condition that can lead to dementia. The study suggests that addressing sleep issues may help prevent cognitive decline.
A new study in mice shows a unique mRNA delivery method can successfully edit faulty genes in fetal brain cells. The technology has the potential to stop progression of genetic-based neurodevelopmental conditions like Angelman syndrome and Rett syndrome before birth.
Researchers found that female mouse models of Rett syndrome have a mosaic-like distribution of cells expressing wild-type and mutant MeCP2 protein, leading to dysregulated genes. The study also discovered an unusual disease progression, with females having more dysregulated genes at the pre-symptomatic stage than later on.
A recent study found that limiting food consumption within a 10-hour window per day improved key indicators of heart health in adults with metabolic syndrome. The study demonstrated significant reductions in blood sugar and cholesterol levels, as well as lower levels of hemoglobin A1c, a marker of long-term blood sugar management.
Researchers identify a homozygous SPAG9 gene mutation associated with intellectual disability, progressive cognitive decline, and heterogeneous brain abnormalities. The study provides a unique model for understanding disruptions in cellular transport mechanisms leading to neurodevelopmental and degenerative brain conditions.
A study found that children with Down's syndrome have an elevated number of red blood cells, which increases their risk of developing leukemia. The extra chromosome 21 alters DNA packing and gene regulation, contributing to the development of leukemia.
A team of scientists has shed light on how the protein MeCP2 interacts with DNA and chromatin, providing new avenues for Rett syndrome therapies. They discovered that MeCP2 dynamically moves on DNA but binds slower to methylated forms, recruiting other regulatory proteins more efficiently.
Researchers tested lecanemab, an anti-amyloid drug, on brain tissue samples from individuals with Down syndrome, finding it effectively targeted amyloid plaques but also bound to blood vessels. The study highlights the need for careful consideration of safety and potential hemorrhagic complications in people with Down syndrome.
Researchers from the Linda Crnic Institute for Down Syndrome identified lower oxygen availability and dysregulated red blood cell function in individuals with Down syndrome. The study highlights potential targets for effective medical interventions to improve oxygen physiology in this population.
A clinical trial shows that JAK inhibitors improve autoimmune conditions such as alopecia areata, atopic dermatitis, and psoriasis in people with Down syndrome. The study also observed improvements in arthritis and decreased biomarkers of autoimmune thyroid disease.
Researchers have identified distinct molecular and immune subtypes across individuals with Down syndrome, providing new insights for personalized medicine approaches. The study's findings could lead to tailored diagnostics and therapeutic approaches, addressing the unique manifestations of co-occurring conditions.
Researchers at the University of Adelaide have developed a non-invasive method to identify rare neurodevelopmental disorders in individuals, utilizing a small skin sample. This breakthrough approach enables the transcription of genetic variations into RNA, aiding in disease-causing gene determination and improving genetic diagnosis.
Researchers found that a cancer drug can restore phagocytosis, a process crucial for brain health, in individuals with Rett syndrome by targeting microglia. The study highlights the potential therapeutic target of microglia in neurological conditions and may lead to new treatments.
Patients with 18q deletion syndrome exhibit both cellular and humoral immunodeficiency, characterized by low immunoglobulin levels and impaired T-cell function. Regular testing for both cellular and humoral immunity can allow for early detection of combined immune deficiencies and improve clinical outcomes.
Researchers at UNC School of Medicine have identified a small molecule that could potentially treat Angelman syndrome by 'turning on' the dormant paternally-inherited UBE3A gene copy. The compound, (S)-PHA533533, has shown excellent uptake in developing brains and bioavailability, making it a promising lead for gene therapy.
Research on mouse models reveals that CBD and metformin can alleviate repetitive behaviour, impaired speech, and learning impairments associated with these genetic conditions. The study also explores the potential for broader use of these treatments in autism spectrum disorder-related conditions.
Researchers found that patients wearing a brain-tracking headband while meditating experienced improved physical functioning and reduced body pain after surgery. The MUSE-2 device provides audio biofeedback to aid meditation.
A case study describes a 50-year-old woman with auto-brewery syndrome, experiencing extreme daytime sleepiness, slurred speech, and elevated blood alcohol levels despite not drinking alcohol. Antifungal medication and low-carbohydrate diets are the main treatment for this rare condition.
Researchers identified a genetic cause of intellectual disability, caused by mutations in the non-coding gene RNU4-2, which affects tens of thousands of people worldwide. The discovery is significant, as it represents one of the most common single-gene genetic causes of neurodevelopmental disorders.
A groundbreaking study has uncovered a significant breakthrough in the diagnosis and monitoring of kidney diseases associated with nephrotic syndrome. Researchers identified anti-nephrin autoantibodies as a reliable biomarker for tracking disease progression, opening new avenues for personalized treatment approaches.
Research presented at Digestive Disease Week 2024 reveals the risks associated with weight-loss drugs and alpha-gal syndrome. Studies found that GLP-1 weight loss drugs may increase the risk of biliary disease and gastroparesis, while an alpha-gal syndrome diagnosis is linked to GI symptoms in females.
The study provides a comprehensive understanding of TRAF7 syndrome, a rare neurological disorder characterized by cardiac, facial, and digital abnormalities. The research highlights the importance of comprehensive clinical assessment and proposes evidence-based guidelines for managing patients with TRAF7-related CAFDADD syndrome.
Researchers developed a gene-based therapy that restored typical cellular function in organoids created from cells of people with Timothy syndrome. The treatment used antisense oligonucleotides to decrease the use of mutated exon 8A and increase reliance on non-affected exon 8, restoring normal calcium channel functioning.
A new study reveals that people with Down syndrome are more prone to developing Alzheimer's disease due to the presence of an extra chromosome 21, which leads to increased amyloid deposits. As a result, cognitive decline occurs in their 50s, whereas autosomal dominant Alzheimer's typically starts later in life.
A new case study suggests that hypoglossal nerve stimulation can improve sleep quality and cognitive development in children with Down syndrome. The procedure has shown promising results in reducing obstructive apnea-hypopnea index and improving neurocognition, offering a potential treatment option for young patients.
The study assessed relationships between TCM syndromes and lung cancer TNM staging indicators, finding phlegm dampness syndrome dominant in stages I & II, Qi Yin deficiency syndrome in stages III & IV. The findings suggest bias in included literature, emphasizing the need for larger sample sizes and clinical experimental investigations.
A new study found similarities in protein structures of Aβ and tau filaments between individuals with Alzheimer's disease and those with both conditions. This knowledge is crucial for understanding Alzheimer's disease in people with Down syndrome and assessing clinical trial inclusion.
A new study published in CANCER reveals that individuals with worsening metabolic syndrome are at a higher risk of developing various types of cancer. The study followed 44,115 adults in China and found that those with an elevated-increasing pattern of metabolic syndrome scores had a significantly higher risk of developing multiple typ...
Researchers identified six cases of Down syndrome and one case of Edwards syndrome in ancient human remains from Spain, Bulgaria, Finland, and Greece dating back to 4,500 years ago. The individuals were buried with care and special grave goods, indicating they were appreciated by their societies.
Researchers found that manual therapy provided a moderate and statistically significant reduction in disability among adults with sacroiliac joint pain syndrome. However, the efficacy of manual therapy for pain related to this syndrome is unclear at this time.
Thrombocytopenia is the third most prevalent symptom of antiphospholipid syndrome, but its cause remains poorly understood. Researchers have unveiled a new mechanism driving thrombocytopenia and identified calprotectin as a potential biomarker for APS-related thrombocytopenia.
People with polycystic ovary syndrome may experience lower memory and thinking skills, as well as subtle brain changes at midlife. Researchers found an association between the condition and cognitive decline, but additional research is needed to confirm these findings.
Researchers at the Francis Crick Institute and UCL have identified a gene that causes heart defects in Down syndrome, a condition resulting from an extra copy of chromosome 21. Reducing the overactivity of this gene partially reversed these defects in mice, setting the scene for potential future therapies.
A study by the University of Gothenburg found that children born with Down syndrome and congenital heart defects have better survival rates since 1990. However, their mortality rate is still 85% higher than others with a congenital heart defect but without Down syndrome.
A multisite clinical trial will evaluate repurposed FDA-approved drugs as treatment options for patients with Rett syndrome, a rare genetic neurodevelopmental disorder affecting brain development. The study aims to find new therapies to improve the lives of individuals with Rett syndrome, potentially providing multiple treatment options.
A new study found that stress drives up inflammation in the body, which is linked to metabolic syndrome. Stress management techniques may be a way to improve biological health outcomes. The research suggests that reducing inflammation can help mitigate the connection between stress and metabolic syndrome.
Researchers at the Francis Crick Institute have identified the first prehistoric person with mosaic Turner syndrome, characterized by one X chromosome instead of two. The study also found the earliest known incidence of Jacob's syndrome, Klinefelter syndrome, and an infant with Down Syndrome in ancient DNA samples.
Researchers at Texas A&M University have been awarded a grant to study bone regeneration throughout the lifespan to benefit individuals with Down syndrome. They hope to understand whether bone regeneration can help people with Down syndrome recover from fractures, and also develop new treatments for limb loss.
A breakthrough study found that light exercise can improve cognitive health in adults with Down syndrome, leading to improved information processing and attention. After just eight weeks of walking, participants showed significant increases in physical fitness and reductions in errors during cognitive assessments.
Researchers at the University of Pittsburgh have discovered a potential new target for treating Barth syndrome, a rare genetic disease with devastating consequences. They identified a molecular culprit that could be targeted to potentially reverse the disease course and developed a small-molecule drug candidate to correct genetic tafaz...
A team of researchers aims to develop drug therapies by targeting genes that affect metabolism in people with Down syndrome, potentially improving their quality of life. The project will focus on the protein SIM2, which has been linked to breast cancer and metabolic changes in individuals with the condition.
A new study by Boston University School of Public Health finds that adults with Down syndrome are more consistently enrolled in Medicaid and utilize more healthcare services than people without developmental disabilities. However, racial disparities exist, with White individuals having greater access to care.
New research from Cold Spring Harbor Laboratory explores how adult brains adapt through critical periods of learning, such as caring for young. MECP2 dysfunction causes neurodevelopmental disorder Rett syndrome, but the study finds that brain circuits can be rapidly rewired in adults.
Researchers found that a compound derived from hops, TXN, can combat metabolic syndrome by reducing the population of Oscillibacter species in the gut microbiome. This reduction leads to reduced inflammation in adipose tissue and improved glucose metabolism.
A study by researchers at the University of Tokyo found that the presynaptic Ube3a E3 ligase molecule plays a key role in eliminating neural synapses. This discovery offers insights into developmental disorders such as Angelman syndrome and autism spectrum disorders.